Activation of the Adipose Tissue NLRP3 Inflammasome Pathway in Cancer Cachexia

Imagem de Miniatura
Arquivos
art_JESUS_Activation_of_the_Adipose_Tissue_NLRP3_Inflammasome_Pathway_2021.PDF (1.3 MB)
Citações na Scopus
4
Tipo de produção
article
Data de publicação
2021
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
FRONTIERS MEDIA SA
Autores
RADLOFF, Katrin
FIGUEREDO, Raquel Galvao
ROSA-NETO, Jose Cesar
MATOS-NETO, Emidio Marques
Citação
FRONTIERS IN IMMUNOLOGY, v.12, article ID 729182, 11p, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Cachexia is a paraneoplastic syndrome that accompanies and compromises cancer treatment, especially in advanced stages, affecting the metabolism and function of several organs. The adipose tissue is the first to respond to the presence of the tumor, contributing to the secretion of factors which drive the systemic inflammation, a hallmark of the syndrome. While inflammation is a defensive innate response, the control mechanisms have been reported to be disrupted in cachexia. On the other hand, little is known about the role of NLRP3 inflammasome in this scenario, a multiprotein complex involved in caspase-1 activation and the processing of the cytokines IL-1 beta and IL-18.</p> Aim based on the evidence from our previous study with a rodent model of cachexia, we examined the activation of the NLRP3 inflammasome pathway in two adipose tissue depots obtained from patients with colorectal cancer and compared with that another inflammatory pathway, NF-kappa B.</p> Results For CC we found opposite modulation in ScAT and PtAT for the gene expression of TLR4, Caspase-1 (cachectic group) and for NF-kappa B p50, NF-kappa B p65, IL-1 beta. CD36, expression was decreased in both depots while that of NLRP3 and IL-18 was higher in both tissues, as compared with controls and weight stable patients (WSC). Caspase-1 basal protein levels in the ScAT culture supernatant were higher in WSC and (weight stable patients) CC, when compared to controls. Basal ScAT explant culture medium IL-1 beta and IL-18 protein content in ScAT supernatant was decreased in the WSC and CC as compared to CTL explants.</p> Conclusions The results demonstrate heterogeneous responses in the activation of genes of the NLRP3 inflammasome pathway in the adipose tissue of patients with cancer cachexia, rendering this pathway a potential target for therapy aiming at decreasing chronic inflammation in cancer.</p>
Palavras-chave
neoplasms, cachexia, adipose tissue heterogeneity, inflammation, NLRP3 inflammasome
URI
https://observatorio.fm.usp.br/handle/OPI/43674
Referências
  1. Ahechu P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02918
  2. Al-Zhoughbi W, 2014, SEMIN ONCOL, V41, P281, DOI 10.1053/j.seminoncol.2014.02.005
  3. Alves MJ, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3178-8
  4. Anderson LJ, 2017, CURR ONCOL REP, V19, DOI 10.1007/s11912-017-0562-0
  5. Anker MS, 2019, J CACHEXIA SARCOPENI, V10, P22, DOI 10.1002/jcsm.12402
  6. Aoyagi T, 2015, WORLD J GASTRO ONCOL, V7, P17, DOI 10.4251/wjgo.v7.i4.17
  7. Baracos VE, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2017.105
  8. Batista ML, 2012, J ENDOCRINOL, V215, P363, DOI 10.1530/JOE-12-0307
  9. Batista ML, 2012, CYTOKINE, V57, P9, DOI 10.1016/j.cyto.2011.10.008
  10. Batista ML, 2016, J CACHEXIA SARCOPENI, V7, P37, DOI 10.1002/jcsm.12037
  11. Becker C, 2013, GASTROENTEROLOGY, V144, P283, DOI 10.1053/j.gastro.2012.11.035
  12. Bertevello PS, 2001, BRAZ J MED BIOL RES, V34, P1161, DOI 10.1590/S0100-879X2001000900009
  13. Bing C, 2009, P NUTR SOC, V68, P385, DOI 10.1017/S0029665109990267
  14. Broz P, 2016, NAT REV IMMUNOL, V16, P407, DOI 10.1038/nri.2016.58
  15. Camargo RG, 2015, NUTRIENTS, V7, P4465, DOI 10.3390/nu7064465
  16. Chamaillard M, 2003, CELL MICROBIOL, V5, P581, DOI 10.1046/j.1462-5822.2003.00304.x
  17. Choi JSA., 2014, J LEUKOCYTE BIOL, V7, P193, DOI [10.14348/mollcells.2014.0104, DOI 10.14348/MOLLCELLS.2014.0104]
  18. Cildir G, 2016, TRENDS MOL MED, V22, P414, DOI 10.1016/j.molmed.2016.03.002
  19. de Matos-Neto EM, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00629
  20. Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0
  21. Deng T, 2016, ANNU REV PATHOL-MECH, V11, P421, DOI 10.1146/annurev-pathol-012615-044359
  22. Dev R, 2019, ANN PALLIAT MED, V8, P24, DOI 10.21037/apm.2018.08.07
  23. Dupaul-Chicoine J, 2010, IMMUNITY, V32, P367, DOI 10.1016/j.immuni.2010.02.012
  24. Evans WJ, 2008, CLIN NUTR, V27, P793, DOI 10.1016/j.clnu.2008.06.013
  25. Fearon KCH, 2012, CELL METAB, V16, P153, DOI 10.1016/j.cmet.2012.06.011
  26. Federico A, 2010, WORLD J GASTROENTERO, V16, P4762, DOI 10.3748/wjg.v16.i38.4762
  27. Giuliani C, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00471
  28. Grant RW, 2015, OBESITY, V23, P512, DOI 10.1002/oby.21003
  29. Guerra F, 2019, CANCERS, V11, DOI 10.3390/cancers11081096
  30. Heni M, 2011, OBESITY, V19, P1004, DOI 10.1038/oby.2010.251
  31. Henriques FS, 2017, FASEB J, V31, P1976, DOI 10.1096/fj.201601151R
  32. Hirota SA, 2011, INFLAMM BOWEL DIS, V17, P1359, DOI 10.1002/ibd.21478
  33. Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86
  34. Karin M, 2020, WIEN KLIN WOCHENSCHR, V132, P431, DOI 10.1007/s00508-020-01671-4
  35. Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870
  36. Karki R, 2019, NAT REV CANCER, V19, P197, DOI 10.1038/s41568-019-0123-y
  37. Karki R, 2017, CANCER IMMUNOL RES, V5, P94, DOI 10.1158/2326-6066.CIR-16-0269
  38. Khatami M, 2011, EXPERT OPIN BIOL TH, V11, P1419, DOI 10.1517/14712598.2011.592826
  39. Kolb R, 2014, PROTEIN CELL, V5, P12, DOI 10.1007/s13238-013-0001-4
  40. Kopp A, 2009, OBESITY, V17, P648, DOI 10.1038/oby.2008.607
  41. Li YJ, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-87
  42. Lim DR., 2017, MED US, V96, P1, DOI [10.1097/MD.0000000000008241, DOI 10.1097/MD.0000000000008241]
  43. Lin L, 2012, J AM SOC NEPHROL, V23, P1329, DOI 10.1681/ASN.2011111123
  44. Lira FS, 2009, CELL BIOCHEM FUNCT, V27, P71, DOI 10.1002/cbf.1540
  45. Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
  46. Lurje G, 2009, PHARMACOGENET GENOM, V19, P95, DOI 10.1097/FPC.0b013e32831a9ad1
  47. Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3
  48. Menu P, 2011, CLIN EXP IMMUNOL, V166, P1, DOI 10.1111/j.1365-2249.2011.04440.x
  49. Ministerio Da Saude. Instituto Nacional do Cancer Jose Alencar Gomes Da Silva (INCA), 2019, EST 2020 INC CANC NO
  50. Neves RX, 2016, J CACHEXIA SARCOPENI, V7, P193, DOI 10.1002/jcsm.12041
  51. Paramel GV, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/846782
  52. Patel M, 2018, BRIT J CANCER, V118, P705, DOI 10.1038/bjc.2017.441
  53. Pietka TA, 2014, DIABETES CARE, V37, P1990, DOI 10.2337/dc13-2835
  54. Neto NIP, 2018, J CACHEXIA SARCOPENI, V9, P1101, DOI 10.1002/jcsm.12345
  55. Qin Qiong, 2017, Chronic Dis Transl Med, V3, P51, DOI 10.1016/j.cdtm.2017.02.004
  56. Rakoff-Nahoum S, 2009, NAT REV CANCER, V9, P57, DOI 10.1038/nrc2541
  57. Rathinam VAK, 2018, TRENDS MOL MED, V24, P304, DOI 10.1016/j.molmed.2018.01.004
  58. Riccardi DM., 2015, THESIS U SAO PAULO I
  59. Santosa S, 2015, INT J OBESITY, V39, P874, DOI 10.1038/ijo.2014.185
  60. Schaffaler A, 2010, TRENDS IMMUNOL, V31, P228, DOI 10.1016/j.it.2010.03.001
  61. Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040
  62. Seelaender MCL, 2014, HORM MOL BIOL CLIN I, V17, P5, DOI 10.1515/hmbci-2013-0040
  63. Sharma BR, 2021, NAT IMMUNOL, V22, P550, DOI 10.1038/s41590-021-00886-5
  64. Sheedy FJ, 2013, NAT IMMUNOL, V14, P812, DOI 10.1038/ni.2639
  65. Silverio R, 2017, LIPIDS HEALTH DIS, V16, DOI 10.1186/s12944-017-0547-x
  66. Szalowska E, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-71
  67. Vaitkus JA, 2017, EXP BIOL MED, V242, P473, DOI 10.1177/1535370216683282
  68. Vatier C, 2012, NUTR DIABETES, V2, DOI 10.1038/nutd.2012.29
  69. Villani AC, 2009, NAT GENET, V41, P71, DOI 10.1038/ng.285
  70. Wang B, 2020, PATHOL RES PRACT, V216, DOI 10.1016/j.prp.2019.152737
  71. Wang JC, 2019, THERANOSTICS, V9, P4893, DOI 10.7150/thno.36037
  72. World Cancer Research Fund/American Institute for Cancer Research, 2018, DIET NUTR PHYS ACT C
  73. Wronska A, 2012, ACTA PHYSIOL, V205, P194, DOI 10.1111/j.1748-1716.2012.02409.x
  74. Yamashita AS, 2017, CYTOKINE, V89, P122, DOI 10.1016/j.cyto.2016.02.015
  75. Zaki MH, 2010, IMMUNITY, V32, P379, DOI 10.1016/j.immuni.2010.03.003
  76. Zaki MH, 2010, J IMMUNOL, V185, P4912, DOI 10.4049/jimmunol.1002046
  77. Zhang J, 2014, MUCOSAL IMMUNOL, V7, P1139, DOI 10.1038/mi.2014.1
  78. Zoico E, 2017, OBESITY, V25, pS87, DOI 10.1002/oby.22008

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCG
Artigos e Materiais de Revistas Científicas - HU
Artigos e Materiais de Revistas Científicas - LIM/08
Artigos e Materiais de Revistas Científicas - LIM/26
Artigos e Materiais de Revistas Científicas - ODS/03